Drug Trial Radar · NCT01895309
A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Last checked: Nov 20, 2026Latest source record: Aug 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
596
Actual
Start
Jun 2013
Primary completion
Apr 2014
Study completion Oct 2015
Sponsor
- Lead sponsor
- Samsung Bioepis Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB4 compared to Enbrel in subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX) therapy. In some countries, after 52 weeks of treatment with either SB4 or Enbrel, subjects will be enrolled into an open label extension period. Subjects will receive SB4 for an additional 48 weeks.
Conditions
- Rheumatoid Arthritis
Interventions
Enbrel (etanercept)Drug
SB4 (proposed biosimilar to etanercept)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- American College of Rheumatology 20% Response Criteria (ACR20)Time frame: Week 24
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site
Kielce, Poland
Investigational Site
Southampton, Hampshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.